Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Nutra Pharma Awarded Grant Under the Qualifying Therapeutic Discovery Project Program
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
"It is an honor to receive this grant and to be recognized by the United States Federal Government for our work developing novel analgesics," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We intend to use the proceeds from this grant to support our ongoing clinical development program for our pain relievers, which include Cobroxin and Nyloxin," he added.
The QTDP Program was enacted in 2010 by the United States Congress as part of the Patient Protection and Affordable Care Act. To be eligible for the grant, a project must demonstrate potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce the long-term growth of health care costs in the United States, or significantly advance the goal of curing cancer within 30 years.
The QTDP Program was enacted in 2010 by the United States Congress as part of the Patient Protection and Affordable Care Act. To be eligible for the grant, a project must demonstrate potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce the long-term growth of health care costs in the United States, or significantly advance the goal of curing cancer within 30 years.
